Retatrutide is the most talked-about weight-loss drug that nobody can legally buy. Eli Lilly’s experimental once-weekly injection has produced average weight loss approaching 30% in clinical trials, and searches for it have surged — many of them for “retatrutide peptide,” sold online by unregulated vendors. Here is what the drug is, what the trials show, and why the online versions are a gamble.

What retatrutide is

Today’s leading obesity drugs mimic gut hormones. Semaglutide (Wegovy, Ozempic) activates the GLP-1 receptor; tirzepatide (Zepbound, Mounjaro) activates both GLP-1 and GIP. Retatrutide adds a third: the glucagon receptor. That is why it is nicknamed a “triple G” or triple agonist. GLP-1 and GIP mainly reduce appetite and improve blood sugar; glucagon is thought to raise energy expenditure and help the liver burn fat. The combination is designed to produce more weight loss than either of the current drugs.

What the trials show

In TRIUMPH-1, reported in May 2026, 2,339 adults with obesity were randomly assigned to one of three doses or placebo for 80 weeks. Among people who stayed on treatment, weight loss averaged:

  • 19.0% on 4 mg
  • 25.9% on 9 mg
  • 28.3% (about 70 pounds) on 12 mg
  • 2.2% on placebo

Counting everyone regardless of whether they kept taking it, the 12 mg figure was 25.0%. Remarkably, 45% of people on the top dose lost at least 30% of their body weight. Other Phase 3 trials have shown 28.7% weight loss at 68 weeks in people with knee osteoarthritis (along with less joint pain), up to 20.8% in people with type 2 diabetes, and up to 22.6% in people with heart disease. For comparison, tirzepatide’s pivotal trial produced around 20% at its top dose.

Beyond weight: the liver

The glucagon component may bring benefits beyond the scale. Glucagon pushes the liver to burn stored fat, and in an earlier Phase 2 substudy most participants on the higher doses saw liver fat fall to normal levels. That has made retatrutide a candidate for fatty liver disease (MASLD), which is common in people with obesity and type 2 diabetes. Lilly is also studying it in kidney disease and other obesity-related conditions.

Side effects

The side effects look like those of other GLP-1-based drugs, but more frequent at higher doses. On 12 mg in TRIUMPH-1, nausea affected 42% of people (versus 15% on placebo) and diarrhea 32% (versus 14%). A less familiar one was dysesthesia — unusual skin sensations such as tingling or sensitivity — reported by 12.5% on the top dose versus 1% on placebo. About 11% of people on 12 mg stopped treatment because of side effects, compared with about 5% on placebo.

When could it be approved?

Retatrutide is not approved anywhere. Lilly plans to submit it to the FDA in early 2027, after several more Phase 3 readouts. A standard FDA review usually takes around ten months to a year after filing, so an approved, pharmacy-dispensed retatrutide is unlikely before late 2027 at the earliest.

What “research peptide” retatrutide is

In the meantime, websites sell vials labeled “retatrutide” as a “research peptide,” usually as a powder to be mixed with bacteriostatic water, and often marked “for research use only” or “not for human consumption.” None of these products come from Lilly, which is the only company making retatrutide for its trials. Their contents are whatever the seller put in them.

The FDA does not accept the “research use only” label as a loophole. In a March 2026 warning letter to one seller, the agency said that such disclaimers do not override marketing that shows the product is intended for people, and that it considers these to be unapproved new drugs. On August 24, 2026, it sent warning letters to five more online sellers marketing retatrutide and related products. Lilly has filed lawsuits against med spas, a compounding pharmacy and other vendors it accuses of selling counterfeit retatrutide.

Why it’s risky

The FDA’s core warning is simple: with unapproved injectables there is no assurance of sterility, potency, purity or safety. In practice that means a vial may contain the wrong amount of drug, a different drug, contaminants, or bacteria, and injection bypasses the body’s usual defenses. Mixing and measuring powders at home adds the risk of dosing errors, and the doses being traded online are often guesses based on trial reports.

The harms are showing up. Use of products claiming to contain retatrutide rose about 1.8-fold every quarter from late 2023 to early 2026, according to one analysis, which also reported less weight loss and more cardiovascular effects than in the trials. Poison-center exposures linked to these products averaged about 95 a month in early 2026, according to CBS News reporting, a sharp rise from the year before.

Safer options

People interested in retatrutide have better routes. Clinical trials of retatrutide and other next-generation drugs are listed at ClinicalTrials.gov, and participants receive genuine drug under medical supervision. Meanwhile, several effective treatments are approved: weekly injections such as Zepbound and Wegovy, and daily pills such as Foundayo and the Wegovy pill, which we compared here. A doctor or pharmacist can help weigh options, costs and coverage. This explainer is general information, not medical advice.